Atlas FDA

TorEx Lung Perfusion System

FDA premarket approval P250025 · decided 2026-07-15

Approval details

PMA number
P250025
Trade name
TorEx Lung Perfusion System
Generic name
Normothermic preservation system for transplantation of initially unacceptable donor lungs
Applicant
Traferox Technologies, Inc.
Date received
2025-07-07
Decision date
2026-07-15
Days to decision
373 days
Decision code
APPR
Product code
PHO
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Mississauga
Statement
The TorEx Lung Perfusion System is indicated for use in continuous normothermic machine perfusion of donor lungs, initially deemed unsuitable for transplantation, during which time the ex vivo function of the lungs can be reassessed for transplantation in adults. The TorEx Lung Perfusion System includes a mobile cart with embedded software, single-use sterile Organ Chamber and Cannulae set and is used with TorEx Lung Perfusate solution to perform ex vivo lung perfusion for up to 6 hours.Note: Th

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
VI°Port™ Liver Preservation System (K260456)Traferox Technologies, Inc.2026-06-01
X°Port Lung Preservation System; X°Port Lung Preservation Solution (K243870)Traferox Technologies, Inc.2025-05-01
LungProtect (K240650)Traferox Technologies, Inc.2024-11-26